Posts by Christine Frankovic
Christine Frankovic currently serves in a Senior Business Development Director role at KCAS, supporting West Coast and International Accounts. Having worked in CROs since 1998, she has gathered experience throughout her career in various operations and business development/marketing roles focused in Clinical Operations, Clinical Pharmacology, Bioanalytical/Biomarker, and Central Lab/Kitting services. Prior to joining KCAS upon divestment from AAIPharma in 2009, she has previously worked at AAIPharma, Quintiles, and Hoechst Marion Roussel (now Sanofi). She received her BS in Microbiology at Kansas State University and works out of the San Francisco Bay Area.
Blogs
The benevolent COVID virus has brought our industry many “gifts.” One birthday present is like a jelly of the month club subscription, and it’s impacted all Central Labs and providers of Clinical Sample Collection Kits, without discretion: the shifting un-availability of important kit contents, like vacutainers and polypropylene tubes. While…
Blogs
Biomarkers can be defined and utilized for many purposes. There are disease biomarkers as well as mechanistic or pharmacological biomarkers. To reduce attrition and better understand a therapeutic, it is essential to be able to monitor the effectiveness of the therapeutic during drug development. Measurement of biomarker levels related to…
Blogs
At KCAS, we work with Director, VP, and C-level pharmaceutical and biotech executives that need to measure their drug or the effect of their drug in biological matrix. Many of our customers rely on…
Blogs
If you’re running a clinical or preclinical study, there are many components that you need to think about, plan, and execute. One is “what the heck do I do with these samples we’re collecting”…
Blogs
The 505(b)(2) drug development path, in contrast to traditional development of a new, never been approved drug (described under 505(b)(1) of the Federal Food, Drug, and Cosmetic Act) or ANDA (described under Section 505(j) of the Act) for a generic drug that is no longer under patent…